vs
Astrana Health, Inc.（ASTH）与FMC CORP（FMC）财务数据对比。点击上方公司名可切换其他公司
Astrana Health, Inc.的季度营收约是FMC CORP的1.3倍（$950.5M vs $759.0M），Astrana Health, Inc.净利率更高（0.7% vs -37.0%，领先37.7%），Astrana Health, Inc.同比增速更快（42.9% vs -4.0%），Astrana Health, Inc.自由现金流更多（$-6.0M vs $-628.1M），过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs -14.5%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
FMC公司是总部位于美国宾夕法尼亚州费城的化工制造企业，1883年创立之初以生产杀虫剂为主，后续逐步拓展业务至其他领域。二战期间曾为美国陆军部设计生产两栖履带登陆车，目前在全球拥有7000名员工，业务布局广泛。
ASTH vs FMC — 直观对比
营收规模更大
ASTH
是对方的1.3倍
$759.0M
营收增速更快
ASTH
高出46.9%
-4.0%
净利率更高
ASTH
高出37.7%
-37.0%
自由现金流更多
ASTH
多$622.1M
$-628.1M
两年增速更快
ASTH
近两年复合增速
-14.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $759.0M |
| 净利润 | $6.6M | $-281.2M |
| 毛利率 | — | — |
| 营业利润率 | 1.9% | -10.6% |
| 净利率 | 0.7% | -37.0% |
| 营收同比 | 42.9% | -4.0% |
| 净利润同比 | 184.4% | — |
| 每股收益（稀释后） | $0.12 | $-2.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHFMC
| Q1 26 | — | $759.0M | ||
| Q4 25 | $950.5M | $1.1B | ||
| Q3 25 | $956.0M | $542.2M | ||
| Q2 25 | $654.8M | $1.1B | ||
| Q1 25 | $620.4M | $791.4M | ||
| Q4 24 | $665.2M | $1.2B | ||
| Q3 24 | $478.7M | $1.1B | ||
| Q2 24 | $486.3M | $1.0B |
净利润ASTHFMC
| Q1 26 | — | $-281.2M | ||
| Q4 25 | $6.6M | $-1.7B | ||
| Q3 25 | $373.0K | $-569.3M | ||
| Q2 25 | $9.4M | $66.7M | ||
| Q1 25 | $6.7M | $-15.5M | ||
| Q4 24 | $-7.8M | $-16.3M | ||
| Q3 24 | $16.1M | $65.0M | ||
| Q2 24 | $19.2M | $295.1M |
毛利率ASTHFMC
| Q1 26 | — | — | ||
| Q4 25 | — | 39.8% | ||
| Q3 25 | — | 23.8% | ||
| Q2 25 | — | 38.7% | ||
| Q1 25 | — | 40.0% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 36.3% | ||
| Q2 24 | — | 38.3% |
营业利润率ASTHFMC
| Q1 26 | — | -10.6% | ||
| Q4 25 | 1.9% | -130.8% | ||
| Q3 25 | 2.0% | -73.1% | ||
| Q2 25 | 3.1% | 12.0% | ||
| Q1 25 | 3.3% | 7.4% | ||
| Q4 24 | 0.1% | 19.2% | ||
| Q3 24 | 5.9% | 12.7% | ||
| Q2 24 | 6.2% | 6.0% |
净利率ASTHFMC
| Q1 26 | — | -37.0% | ||
| Q4 25 | 0.7% | -158.8% | ||
| Q3 25 | 0.0% | -105.0% | ||
| Q2 25 | 1.4% | 6.3% | ||
| Q1 25 | 1.1% | -2.0% | ||
| Q4 24 | -1.2% | -1.3% | ||
| Q3 24 | 3.4% | 6.1% | ||
| Q2 24 | 3.9% | 28.4% |
每股收益（稀释后）ASTHFMC
| Q1 26 | — | $-2.25 | ||
| Q4 25 | $0.12 | $-13.77 | ||
| Q3 25 | $0.01 | $-4.52 | ||
| Q2 25 | $0.19 | $0.53 | ||
| Q1 25 | $0.14 | $-0.12 | ||
| Q4 24 | $-0.14 | $-0.13 | ||
| Q3 24 | $0.33 | $0.52 | ||
| Q2 24 | $0.40 | $2.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | $390.9M |
| 总债务越低越好 | — | $2.8B |
| 股东权益账面价值 | $779.3M | $1.8B |
| 总资产 | $2.2B | $9.4B |
| 负债/权益比越低杠杆越低 | — | 1.50× |
8季度趋势，按日历期对齐
现金及短期投资ASTHFMC
| Q1 26 | — | $390.9M | ||
| Q4 25 | $429.5M | $584.5M | ||
| Q3 25 | $463.4M | $497.7M | ||
| Q2 25 | $342.1M | $438.2M | ||
| Q1 25 | $260.9M | $315.3M | ||
| Q4 24 | $290.8M | $357.3M | ||
| Q3 24 | $350.3M | $416.7M | ||
| Q2 24 | $327.7M | $471.5M |
总债务ASTHFMC
| Q1 26 | — | $2.8B | ||
| Q4 25 | — | $3.4B | ||
| Q3 25 | — | $3.4B | ||
| Q2 25 | — | $3.4B | ||
| Q1 25 | — | $3.1B | ||
| Q4 24 | — | $3.1B | ||
| Q3 24 | — | $3.1B | ||
| Q2 24 | — | $3.1B |
股东权益ASTHFMC
| Q1 26 | — | $1.8B | ||
| Q4 25 | $779.3M | $2.1B | ||
| Q3 25 | $775.5M | $3.8B | ||
| Q2 25 | $765.5M | $4.4B | ||
| Q1 25 | $745.4M | $4.4B | ||
| Q4 24 | $712.7M | $4.5B | ||
| Q3 24 | $704.6M | $4.6B | ||
| Q2 24 | $678.9M | $4.6B |
总资产ASTHFMC
| Q1 26 | — | $9.4B | ||
| Q4 25 | $2.2B | $9.7B | ||
| Q3 25 | $2.2B | $12.1B | ||
| Q2 25 | $1.4B | $12.3B | ||
| Q1 25 | $1.3B | $11.8B | ||
| Q4 24 | $1.4B | $11.7B | ||
| Q3 24 | $1.3B | $12.2B | ||
| Q2 24 | $1.3B | $12.1B |
负债/权益比ASTHFMC
| Q1 26 | — | 1.50× | ||
| Q4 25 | — | 1.62× | ||
| Q3 25 | — | 0.89× | ||
| Q2 25 | — | 0.76× | ||
| Q1 25 | — | 0.71× | ||
| Q4 24 | — | 0.69× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | — |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | $-628.1M |
| 自由现金流率自由现金流/营收 | -0.6% | -82.8% |
| 资本支出强度资本支出/营收 | 0.3% | 2.2% |
| 现金转化率经营现金流/净利润 | -0.44× | — |
| 过去12个月自由现金流最近4个季度 | $104.5M | $-154.0M |
8季度趋势，按日历期对齐
经营现金流ASTHFMC
| Q1 26 | — | — | ||
| Q4 25 | $-2.9M | $657.1M | ||
| Q3 25 | $10.0M | $-184.2M | ||
| Q2 25 | $90.9M | $65.9M | ||
| Q1 25 | $16.6M | $-545.0M | ||
| Q4 24 | $-10.9M | $427.9M | ||
| Q3 24 | $34.0M | $159.5M | ||
| Q2 24 | $23.2M | $292.2M |
自由现金流ASTHFMC
| Q1 26 | — | $-628.1M | ||
| Q4 25 | $-6.0M | $631.1M | ||
| Q3 25 | $7.4M | $-207.9M | ||
| Q2 25 | $89.5M | $50.9M | ||
| Q1 25 | $13.6M | $-576.6M | ||
| Q4 24 | $-13.5M | $406.3M | ||
| Q3 24 | $31.7M | $143.8M | ||
| Q2 24 | $20.4M | $282.3M |
自由现金流率ASTHFMC
| Q1 26 | — | -82.8% | ||
| Q4 25 | -0.6% | 58.3% | ||
| Q3 25 | 0.8% | -38.3% | ||
| Q2 25 | 13.7% | 4.8% | ||
| Q1 25 | 2.2% | -72.9% | ||
| Q4 24 | -2.0% | 33.2% | ||
| Q3 24 | 6.6% | 13.5% | ||
| Q2 24 | 4.2% | 27.2% |
资本支出强度ASTHFMC
| Q1 26 | — | 2.2% | ||
| Q4 25 | 0.3% | 2.4% | ||
| Q3 25 | 0.3% | 4.4% | ||
| Q2 25 | 0.2% | 1.4% | ||
| Q1 25 | 0.5% | 4.0% | ||
| Q4 24 | 0.4% | 1.8% | ||
| Q3 24 | 0.5% | 1.5% | ||
| Q2 24 | 0.6% | 1.0% |
现金转化率ASTHFMC
| Q1 26 | — | — | ||
| Q4 25 | -0.44× | — | ||
| Q3 25 | 26.69× | — | ||
| Q2 25 | 9.65× | 0.99× | ||
| Q1 25 | 2.48× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.11× | 2.45× | ||
| Q2 24 | 1.21× | 0.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
FMC
| EMEA | $307.0M | 40% |
| North America | $198.0M | 26% |
| Latin America | $177.0M | 23% |
| Asia (excluding 2026 India) 1 | $81.0M | 11% |
